

ORENCIA (ABATACEPT)

INFUSION ORDERS

FAX: 470.922.3656 | **PHONE:** 470.377.6400

PATIENT INFORMAT	ION: Fax comple	eted form, insurance information,	and clinical documentation to 470.922.3656	
Patient Name:		DOB:	Phone:	
Patient Status: New to		Therapy Next Treatme	nt Date:	
MEDICAL INFORMAT	ION			
Diagnosis: CRheumato		ular Juvenile Idiopathic Artl :	hritis Psoriatic Arthritis	
ICD-10 Code :				
Patient Weight: Ib	s. (required) Allergies: _			
THERAPY ORDER				
Orencia Dose:	mg IV Other do	ose:	**Max dose: 1000mg**	
Frequency: 0, 2, 4 weeks, and every 4 weeks thereafter x 1 year Image: Description Image: Description betweeks x 1 year Image: Other: Image: Description betweeks x 1 year Image: Description betweeks x 1 year				
Pre-Medication Orders: Tylenol □ 1000mg □ 500mg PO, please choose one antihistamine: □ Cetirizine 10mg PO □ Diphenhydramine 25mg PO □ Loratadine 10mg PO				
Additional Pre-Medication	□Solu-Cor	I mg IVP tef mg IVP		
Lab Orders:		Frequency: Monthly	□ Other:	
□ Yearly QFT TB screening (optional) □ Baseline HepBcAB total				
Required labs to be drawn by: Biocare Infusion Referring Provider				
Other:				
 15-30kg (33-66lbs Diphenhydramine: Adm Refer to physician order Flush orders: NS 1-20mL 	patient weight) piPen 0.3mg or compound): EpiPen Jr. 0.15mg or co inister 25-50mg orally OR r or institutional protocol fo pre/post infusion PRN and	ompounded syringe IM or so IV (adult) r pediatric dosing	ay repeat in 5-10 minutes x1 ubQ; may repeat in 5-10 minutes x1 mL per protocol as indicated PRN	
PROVIDER INFORM				
agent in dealing with medical and prescription	insurance companies, and to select the	preferred site of care for the patient	Date: Contact Person: of care):	
PREFERRED LOCATION				
City:	State:	View our locatio	ons here:	
IMPORTANT NOTICE: This fax is intende		OCAREINFUSION.COM	ential, privileged property, or exempt from disclosure under	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR ORENCIA (ABATACEPT) THERAPY

PATIENT INFORMATION:			
Patient Name: DOB:			
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL			
Include signed and completed order (MD/prescriber to complete page 1)			
□ Include patient demographic information and insurance information			
Include patient's medication list			
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy			
☐ Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)? ☐ Yes □ No If yes, which drug(s)?			
Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Enbrel, Simponi, Cimzia)?			
☐ GVHD - Will Orencia be used in combination with a calcineurin inhibitor (i.e., cyclosporine, tacrolimus) and methotrexate? ☐ Yes ☐ No			
☐ Include labs and/or test results to support diagnosis			
☐ i.e., RF, anti-CCP, ESR, C-reactive protein			
If applicable - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a wash- out period of weeks prior to starting Orencia.			
Other medical necessity:			
REQUIRED PRE-SCREENING			
☐ TB screening test completed within 12 months - attach results □Positive □ Negative			
Hepatitis B screening test (Hepatitis B surface antigen) - attach results Positive Negative			

*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.